IRIS
LADETTO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.797
AS - Asia 3.548
NA - Nord America 3.414
SA - Sud America 844
AF - Africa 145
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 4
Totale 12.762
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.287
RU - Federazione Russa 1.867
SG - Singapore 1.418
IE - Irlanda 1.350
HK - Hong Kong 693
BR - Brasile 656
CN - Cina 553
VN - Vietnam 477
SE - Svezia 319
DE - Germania 276
UA - Ucraina 247
IT - Italia 244
FR - Francia 223
IN - India 90
GB - Regno Unito 73
AR - Argentina 67
FI - Finlandia 65
BJ - Benin 59
CA - Canada 55
MX - Messico 53
ID - Indonesia 52
EC - Ecuador 43
BD - Bangladesh 40
KR - Corea 35
IQ - Iraq 32
JP - Giappone 32
NL - Olanda 28
ZA - Sudafrica 27
PL - Polonia 23
CO - Colombia 20
AT - Austria 19
TR - Turchia 19
CL - Cile 15
PK - Pakistan 15
VE - Venezuela 15
EG - Egitto 14
UZ - Uzbekistan 13
SA - Arabia Saudita 12
ES - Italia 11
LT - Lituania 11
PE - Perù 11
PY - Paraguay 11
MA - Marocco 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
IR - Iran 9
KE - Kenya 9
DZ - Algeria 7
EU - Europa 6
PH - Filippine 6
AU - Australia 4
BO - Bolivia 4
CR - Costa Rica 4
GR - Grecia 4
KZ - Kazakistan 4
PT - Portogallo 4
AZ - Azerbaigian 3
BE - Belgio 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
JO - Giordania 3
LB - Libano 3
MY - Malesia 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
TH - Thailandia 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
EE - Estonia 2
HR - Croazia 2
KW - Kuwait 2
PA - Panama 2
SI - Slovenia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
ZM - Zambia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
DK - Danimarca 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
LK - Sri Lanka 1
Totale 12.750
Salva come PNG Salva come JPEG
Città #
Dublin 1.346
Hong Kong 692
San Jose 412
Singapore 392
Jacksonville 296
Ashburn 287
Moscow 254
Wilmington 195
Lauterbourg 192
Lawrence 174
Princeton 174
Ho Chi Minh City 162
San Mateo 145
Chandler 130
Los Angeles 117
Beijing 116
Hanoi 95
Dearborn 84
Buffalo 76
Dallas 66
Cotonou 59
São Paulo 58
New York 52
Redondo Beach 48
Seoul 33
Frankfurt am Main 29
Novara 29
Orem 28
Piemonte 28
Tokyo 28
Boardman 27
Bremen 26
Houston 25
Rio de Janeiro 25
Turin 25
Chennai 24
Falkenstein 24
Ann Arbor 23
Helsinki 23
Santa Clara 22
Tianjin 22
Warsaw 22
Haiphong 21
Da Nang 19
Fairfield 19
Guangzhou 19
Toronto 19
Mexico City 18
Montreal 18
Nuremberg 17
Amsterdam 16
Brasília 16
Brooklyn 16
Quito 16
Atlanta 15
Denver 15
Milan 15
Norwalk 15
Andover 14
Des Moines 14
London 14
Stockholm 14
Council Bluffs 13
Johannesburg 13
Poplar 13
Tashkent 13
Woodbridge 13
Baghdad 12
Mumbai 12
Ninh Bình 12
Thái Bình 12
Vienna 12
Boston 10
Curitiba 10
Shanghai 10
Biên Hòa 9
Brno 9
Chicago 9
Guayaquil 9
Hangzhou 9
Munich 9
Phoenix 9
Porto Alegre 9
Querétaro 9
Belo Horizonte 8
Hefei 8
Jakarta 8
Mülheim 8
Rome 8
Salvador 8
Seattle 8
Shenzhen 8
Asunción 7
Buenos Aires 7
Campinas 7
Cape Town 7
Hải Dương 7
Lima 7
Manchester 7
Menlo Park 7
Totale 6.771
Salva come PNG Salva come JPEG
Nome #
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 133
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 132
STAble: A novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow 132
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 127
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 126
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia 115
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 114
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes 113
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 113
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 112
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 110
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 109
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 107
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 107
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 104
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies 99
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 98
COMPARISON OF TWO REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION PERFORMANCE 96
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 95
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment 95
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 95
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF PROGRESSION AND OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA 94
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia 93
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 92
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 91
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 90
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 90
Genetic and phenotypic attributes of splenic marginal zone lymphoma 90
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 86
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib 85
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma 84
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 84
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 83
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 82
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 81
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice 79
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 77
Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 76
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 76
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes 75
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 75
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 75
CAR-T therapy: the role of the hematopoietic stem cell processing laboratory 74
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients 73
The black swan: a case of central nervous system graft-versus-host disease 72
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors 72
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 71
Controversies in the treatment of follicular lymphoma 70
Droplet Digital PCR Assay for MYD88L265P 70
Pharmacotherapy considerations for patients who develop acute kidney injury during cancer therapy 69
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 69
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 69
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 69
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial 68
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 68
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 68
Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case 68
DEL(13q14) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13q DELETION ALONE OR NORMAL KARYOTYPE 67
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 67
LOW CD49d AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME 67
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests 66
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial 65
Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units 65
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 65
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma 64
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 64
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 64
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 63
LENALIDOMIDE PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB IS SAFE AND EFFECTIVE IN UNTREATED, ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I STUDY BY THE FONDAZIONE ITALIANA LINFOMI 63
TWO MAIN GENETIC PATHWAYS LEAD TO THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME 63
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy 63
The adulthood of MRD detection in MCL 63
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells 62
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial 62
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity 62
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias 62
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma 62
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network 61
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 61
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 61
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 61
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial 61
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 60
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 59
Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 59
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance 58
EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas 58
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 57
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 57
ESMO consensus conference on Malignant lymphoma: Management of ‘ultra-high-risk’ patients 57
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT 57
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma 56
Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study 56
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft 56
The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma 56
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma 55
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission 55
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 55
Home management of hematological patients requiring hospital admission 55
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 55
Totale 7.745
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.252
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.252
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021173 0 0 0 0 0 0 0 0 0 6 158 9
2021/2022794 4 20 143 55 47 0 16 16 81 13 172 227
2022/20231.966 179 37 76 18 69 123 41 93 1.251 8 50 21
2023/2024706 17 29 30 12 160 5 176 10 6 16 38 207
2024/20252.233 45 7 41 14 22 217 152 119 805 391 65 355
2025/20266.186 165 212 578 1.113 537 493 1.007 1.127 528 426 0 0
Totale 13.042